SIDA. 2001. PROJECTES FINANÇATS

Dr  Jesús Almeda Ortega

Almeda J., Casabona J., Simon B., Gerard M., Rey D., Puro V., Thomas T., on behalf of the Euro-NONOPEP Project group. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Eurosurveillance 2004 vol. 9 Issue 2.

Almeda J., Casabona J., Allepuz A., García-Alcaide F., Del Romero J., Tural C., Grupo de Conseso Español sobre Profilaxis Postexposición No Ocupacional al VIH. Recomendaciones para la profilaxis postexposición no ocupacional al VIH. Enferm Infecc Microbiol Clin, 2002; 20(8):391- 400.

Almeda J., Casabona J., Allepuz A., García-Alcaide F., Del Romero J., Tural C., Colom J., Bolao F., Camping M., Oomínguez A., Force L., Jiménez A., Guerra-Romero L. Guidelines fro non-occupational post-exposure HIV prophylaxis. Recommendations of GESIDA/CEESCA TI National Plan on AIDS. Iribarren JA, ed. Gesida Consensus Conferences on Practice Guidelines for the management of HIV infection (2000-2002), Ed. Ooyma SL, Barcelona 2002, 129-142 ISBN: 84-7592-695- 9. 

Almeda J., Casabona J., Allepuz A., García-Alcaide F., Del Romero J., Tural C., Colom J., Bolao F., Camping M., Domínguez A., Force Ll., Jiménez A., Guerra-Romero L., Grupo de Consenso Español sobre Profilaxis Postexposición No Ocupacional al VIH. Recomendaciones para la profilaxis postexposición no ocupacional al VIH. Iribarren JA, ed. Documentos de Consenso de Gesida sobre Terapia Antirretroviral y enfermedades asociadas al VIH (2000-2002), Ed. Ooyma SL, Barcelona 2002, pags. 141-155 ISBN: 84-7592-694-0. 

Almeda J., Allepuz A., Simon G., Casabona J. Conocimientos, actitudes y Prácticas (KAP) respecto a la Profilaxis Post-Exposición al VIH no ocupacional (NONOPEP) en Cataluña. Abstract: CPO5p3. 6° Congreso Nacional sobre el sida. Valencia 3-6 Abril 2001 (SEISIOA). Publicación Oficial de la Sociedad Española Interdisciplinaria del Sida (SEISIOA), Abril 2001; suplo 1, Vol. 12, pago 10

Almeda J., Simon BG., Casabona J., Rey O., Allepuz A., Puro V., Gerard M., Bernasconi E., Bergin C., Evans B., Lazanas M., Marcus U., Mota-Miranda A., Smith E., Tomazic J., Van Den Hoek A., Vetter N. Knowledge, actitudes and practices of physicians on non- occupational post-exposure prophylaxis (NONOPEP) to HIV). XIV International Conference on AIOS. Barcelona, 7-12 July 2002. WePeC6146 en Abstract Book, Volume 2, pago 118.

Simon BG., Almeda J., Casabona J., Rey D., Puro V., Van Den Hoek A., Bernasconi E., Bergin C., Evans B., Lazanas M., Marcus U., Mota-Miranda A., Tomazic J., Gérard M. Characteristics for demand and prescription of non occupational post exposure prophylaxis (NONOPEP) for HIV in Europe. XIV International Conference on AIOS. Barcelona, 7-12 July 2002. MoOr011 08 en Abstract Book, Volume 1, pago 148.

Rey D., Bendiane MK., Moatti JP., Casabona J., Simon BG., Almeda J., Bernasconi E., Bergin C., Evans B., Gerard M., Lazanas M., Marcus U., Mota-Miranda A., Puro E., Smith E., Tomazic J., Van Den Hoek A., Shmidt B., Vetter N. Policy on non-occupational post- exposure prophylaxis for HIV in 14 European countries . XIV International Conference on AIDS. Barcelona, 7-12 July 2002. TuPeF5382 en Abstract Book, Volume 2, pago 612.

Almeda J., Simon BG., Casabona J., García-Alcaide F., Pulido F., Tural C., Del Romero J., Rey D., Grupo Euro-NONOPEP. Exposición Accidental No Ocupacional al VIH. Resultados del registro Europeo de Profilaxis Post-exposición No Ocupacional (NONOPEP) al VIH. Abstract núm.: 327. XX Reunión Científica de la Sociedad Española de Epidemiología, Barcelona, 7-12 July 2002. Gaceta Sanitaria 2002; 16 (Supl.1):127. 

Quesada A., Matas L., Almeda J., Casabona J. Diagnóstico postexposicional precoz de la infección por VIH. Early post-exposure diagnosis of HIV infection. Enferm Infecc Microbiol Clin 2003; 21 (6): 320. 

Almeda J., Allepúz A., Simon BT., Blasco JA., Esteve A., Casabona J. Profilaxis post-exposición al VIH no ocupacional. Conocimientos y prácticas de profesionales y grupos con conductas de riesgo. Med Clin (Barc) 2003; 121 (9):321-326. 

Blackham J., Almeda J. on behalf of the European Project on Non-Occupational Postexposure Prophylaxis for HIV (Euro-NONOPEP). Differences between new United States recommendations and existing European guidelines on the use of postexposure prophylaxis (PEP) following non-occupational exposure. Euro Survein 2005;10: 68-69.

Martín NV., Almeda J., Casabona J. Effectiveness and safety of HIV post-exposure prophylaxis after sexual, injecting-drug-use or other non-occupational exposure.(Protocol) The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CDO05273. DOI: 10.1002/14651858.CDO05273.

Allepúz Palau A., Betty-Germaine Simon Douala, Blasco Amaro J.A., Esteve Gómez A., Casabona i Barabarà J., Almeda Ortega J. Profilaxis post-exposición al VIH no ocupacional. Conocimientos y prácticas de profesionales y grupos con conductas de riesgo. Med Clin (Barc) 2003; 121(9):321-326.

Almeda J, Casabona J, Simon B, Gerard M, Rey D, Puro V, Thomas T, on behalf of the Euro-Nonopep Project Group. Proposed Recommendations for the Management of HIV Post-Exposure Prophylaxis After Sexual, Injecting Drug or Other Exposures in Europe. Euro Surveill 2004; 9: 35-40

Jodi Blackham, Jesús Almeda on behalf of the European Project on Non-Occupational Postexposure Prophylaxis for HIV (Euro-NONOPEP). Differences between new United States recommendations and existing European guidelines on the use of postexposure prophylaxis (PEP) following non-occupational exposure. Euro Surveill 2005;10: 68-69.

Almeda J. Profilaxis tras exposición no ocupacional. AIDS Cyber J [recurs electrònic]. 2006;9(2). Disponible a: http://www.ttmed.com/sida/aids_ cyber.cfm?id_dis=31&ID_Cou=20 [Consultat 10.03.2006]

M. Campins Martí y J. Almeda Ortega. Fundamentos de la profilaxis postexposición frente al VIH. JANO, Medicina y Humanidades 2006; 1604(0): 74-80.

M.K. Bendiane, V. Villes, M.P. Carrieri, J. Almeda, J Casabona, B Spire, D. Rey. Two Years of HIV Non-Occupational Post-Exposure Prophylaxis Requests and Prescriptions in South-East France (Abstract Núm: TUE/11/004) 2005 AIDS IMPACT Conference. Cape Town, South Africa. 4th-7th April 2005. (Disponible en http://www.aidsimpact.net/Programme/Part3.asp).

Almeda J. Putting Non-Occupational PEP Into Practice: What Are the Implications? IAPAC EUROPEAN SESSIONS 2006. 12-13 October 2006 - Budapest. Hungary. (Disponible a: http://www.iapac.org/home.asp?pid=7567

Dr  Jordi Casabona Barbarà

Martró E, Suligoi B, González V, Bossi V, Esteve A, Mei J, and the Recent HIV Infections Study Group. Identification of recent HIV infections in single serum sample: Comparison between the avidity index method and the serologic testing algorithm for recent HIV seroconversion (STARHS). Journal of Clinical Microbiology, vol. 43, No. 12, 2005. p. 6197-6199.

Centre d'Estudis Epidemiològics sobre la Sida de Catalunya, CEESCAT. Sistema integrat de vigilància epidemiològica del l'HIV/ITS a Catalunya (SIVES). Informe anual 2005. Barcelona: Generalitat de Catalunya, Departament de Salut, 2004. Document tècnic CEESCAT, 18.

Centre d'Estudis Epidemiològics sobre la Sida de Catalunya, CEESCAT. Sistema integrat de vigilància epidemiològica del l'HIV/ITS a Catalunya (SIVES). Informe anual 2004. Barcelona: Generalitat de Catalunya, Departament de Salut, 2003. Document tècnic CEESCAT, 17. (Disponible a http://www.ceescat.org/Documents_Esp1.htm)

Dr  Josep Cladera Cerdà

Buzón, V., Padrós, E., Cladera , J. (2005) Interaction of Fusion Peptides from HIV Gp41 with membranas: A Time-Resolved, Membrana-Binding, Lipid Mixing and Structural Study. Biochemistry 44(40):13354-64.

Buzón, V and Cladera, J. (2006) Effect of cholesterol on the interaction of the HIV Gp41 fusion peptide with model membranes. Importance of the membrane dipole potential. Biochemistry 45, 15768-15775.

Dr  Bonaventura Clotet Sala

Dr Santiago Moreno Guillen

Dr Vicente Soriano

Dr  Núria Margall Coscojuela

Dr  Asunción Moreno Camacho

Wensing A.M.J., Vercauteren J., van de Vijver D.A., et al. Spread Programme. Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management http://www.journals.uchicago.edu/JID/journal/issues/v192n6/34030/34030.text.html  J Infect Dis. 2005; 192(6):958-66.

Gutiérrez C., Mendoza C., Erkicia I., et al. Drug-Resistant mutations In HIV-1 Antiretroviral-Naive Individuals between 2003-2004 in Spain. JAIDS Journal (Submitted).

Wensing A.M.J., van de Vijver D.A., Angarano G. et al. Spread Programme. Transmission of drug resistant HIV in Europe remains limited to single classes. AIDS Journal (Submitted).

Dr Pere Domingo Pedrol

Dr  Marta Giralt Oms

Domingo P., Vidal F., Domingo JC. Molecular basis of antiretroviral drugs-associated long-term toxicity: how bad can good drugs be? Curr. Med. Chem. Antiinfective Agents 2004; 3: 109-133.

Rodriguez de la Concepcion ML., Domingo JC., Domingo P., Giralt M., Villarroya F. Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. AIDS. 2004 Apr 9; 18(6): 959-60.

Villarroya F., Domingo P., Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends in Pharmacological Sciences 2005 Febr; 26 (2): 88-93.

Rodríguez de la Concepción ML.,Yubero P., Domingo JC., Iglesias R., Domingo P., Villarroya F., Giralt M. Uncoupling protein-1 and mitochondrial biogenesis are targets of reverse, transcriptase inhibitor-induced toxicity in brown adipocytes (pendent d'enviar a publicar).

Rodríguez de la Concepción ML., Guallar JP., Iglesias R., Yubero P., Domingo JC., Domingo P., Villarroya F., Giralt M. Involvement of the brown adipocyte in pharmacologically induced lipomatosis. Congrés: 13th European Congress on Obesity, Praga (Txequia) 2004. International Journal of Obesity 28 (SuppI1): S 102 (2004).

Rodríguez de la Concepción ML., Yubero P.,  Domingo J.C., Iglesias R., Villarroya F., M Giralt, Domingo P.  Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antiviral Therapy 10 (4): 515-526 (2005)

Villarroya F., Giralt M. ,  Domingo P.,  Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends in Pharmacological Sciences 26 (2): 88-93 (2005)

Vidal F, Domingo JC, Veloso S, Sambeat MA, Torres F, Sirvent J, Vendrell J, Matias-Guiu X, Richart C., Domingo P. Tumor necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy: its role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005 ; 35 : 771-780.

Guallar JP., Vila MR., Lopez-Gallardo E., Solano A.,  Domingo J.C.,  Gamez J.,  Pineda M., Capablo J.L.,  Andreu A.L., Montoya J., Giralt M.,  Villarroya F.,  Domingo P. Altered expression of master regulatory genes of adipogenesis in lipomas from patients bearing tRNA(Lys) point mutations in mitochondrial DNA. Mol Genet Metab 89(3):283-5 (2006)

Giralt M.,  Guallar J.P.,  Rodríguez de la Concepción M.L., Alegre M., Domingo J.C.,  Villarroya F., Domingo P. HIV-1 infection alters gene expression in adipose tissue, contributing to HAART-associated lipodystrophy Antiviral Therapy 11:729-740 (2006)

Muñoz A, Rodríguez Vidigal F, Domingo P. Patogenia de la lipodistrofia y de las alteraciones metabólicas asociadas a la infección por VIH. Med Clin (Barc) 2006; 127: 465-474.

Vidal F., Domingo P. Toxicidad a largo plazo de los análogos de nucleósidos/ nucleótidos. Enferm Infecc Microbiol Clin 2006 ; 5 : 22-29.

Vidal F., Domingo P. Manejo de la toxicidad asociada a análogos de nucleósidos o cómo sustituir fármacos sin incrementar la complejidad del régimen. Enferm Infecc Microbiol Clin 2006 2006; 5: 45-53.

Vidal F., Domingo J.C., Villarroya F., Saumoy M., Giralt M., Guallar J.P., Torres F., Cihlar T., Domingo P. Assessment of the in vitro cytotoxicity and mitochondrial toxicity of tenofovir and its combinations with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006; 50: 3824-3832.

Rodríguez de la Concepción, M.L., Guallar, J.P., Iglesias, R., Yubero, P., Domingo, J.C., Villarroya, F., Giralt, M., Domingo, P.,  Involvement of the brown adipocyte in pharmacologically induced lipomatosis 13th European Congress on Obesity, Praga International Journal of Obesity 28 (Suppl 1): S102 (2004)

Villarroya F., Guallar J.P.,  Rodríguez de la Concepción M.L.,  Domingo J.C., Giralt M., Domingo P.  Adipose tissue disturbances in response to HIV infection and anti-retroviral treatment. From inflammation to mitochondrial toxicity. 14th European Congress on Obesity, Atenes Obesity Reviews 6 (Suppl.1): 9 (2005)

Guallar, J.P., Rodríguez de la Concepción, M.L., Alegre, M., Domingo, J.C., Villarroya, F.; Giralt M., Domingo, P.  HIV-1 infection alters mitochondrial, metabolic and adipokine gene expression in subcutaneous adipose tissue. 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin Antiviral Therapy 10 (Suppl.3): L19 (2005)

Rodriguez de la Concepcion, M.L., Guallar, J.P., Yubero, P., Domingo, J.C., Alegre, M., Iglesias, R., Domingo, P., Giralt, M., Villarroya, F. Role of disturbances of brown with respect to white adipocyte biology in HAART-associated lipodystrophy and lipomatosis. Studies in vitro and in vivo. 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin Antiviral Therapy 10 (Suppl.3): L19 (2005)

Dr José Andrés Esté Araque

Dr Jordi Teixidó Closa

Dr  Josefa Mallol Montero

Barretina J., Blanco J., Bonjoch A., Llano A., Clotet B., Este JA. Immunological and virological study of enfuvirtide-treated HIV -positive patients. AillS 18:1673-82, 2004.

Blanco J., Barretina J., Clotet B., Este JA. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp4l-dependent mechanism. J Leukoc Biol 76: 804-11, 2004.

Blanco J., Bosch B., Fernandez-Figueras MT, Barretina J., Clotet B., Este JA. High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J Biol Chem 279:51305-14, 2004.

Bobardt MD., Armand-Ugon M., Clotet I, Zbang Z., David G., Este JA., Gallay PA. Effect ofpolyanion-resistance on HIV-l infection. Virology 325:389-98, 2004.

Giménez-Barcons, M., Ribera M, Llano A., Clotet B., Esté JA., Martínez MA. Analysis of chemokine and cytokine expression in HIV-l and GB virus-C co infected patients. Clinical Infectious Diseases, 2005 40: 1342-1349.

Menendez-Arias L., Este JA. HIV -resistance to viTal entry inhibitors. Curr Pharm Des 10: 1845-60, 2004.

Pauls E., Este JA. Interferent RNA as a tool in target validation. Drug U Discovery Today, Technologies doi:10.1016/j.ddtec. 2004. 08.005, 2004.

Llano A., Cedeño S., Clotet B., Esté JA. Interleukin- 7 -dependent production of CCL5 (RANTES) may promote the selection of X4 HIV variants (sent).

Bosch B., Blanco J., Clotet-Codina I., Armand-Ugón M., Clotet B., Esté JA. Inhibition of cell-to-cell coreceptor independent HIV-1 transmission by a CD4-IgG2 fusion protein Antimicrob Agents Chemother 2005. 49: 4296-4304.

Fernandez G., Llano A., Clotet B., Esté JA., Martínez MA. Distinct pattem of HIV -1 genetic diversity in subjects with different 1evels of stromal-cell-derived factor 1 (sent).

Colobran R., Adreani P., Ashhab Y., Llano A., Esté JA., Dominguez O., Pujol-Borrell R, Juan M. Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV + patients (sent).

Blanco J., Clotet-Codina I., Bosch B., Armand-Ugón M., Clotet B., Esté JA. A Multiparametric assay to screen and dissect the mode of action of anti-HIV envelope drugs (enviat a publicar).

Armand-Ugón M., Clotet-Codina L., Tintori C., Manetti F., Clotet B., Botta M., Esté JA. The anti-HIV activity of ADS-JI targets the HIV-I gpl20 Virology 2005. 343: 141-149

Bosch, B., I. Clotet-Codina, J. Blanco, E. Pauls, G. Coma, S. Cedeno, F. Mitjans, A. Llano, M. Bofill, B. Clotet, J. Piulats, and J. A. Este. 2006. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Res 69:173-180.

Fernandez, G., A. Llano, M. Esgleas, B. Clotet, J. A. Este, and M. A. Martinez. 2006. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. J Gen Virol 87:1285-1294.

Tintori, I. ,Manetti, F., M. Armand-Ugon, C. Clotet-Codina, M. Armand-Ugon, R. Rigno, J. A. Este, and M. Botta. 2006. A Combination of Molecular Dynamics and Docking Calculations to Explore the Binding Mode of ADS-J1, a Polyanionic Compound Endowed with Anti-HIV-1 Activity. Journal of chemical information and computer sciences. 46, 1344-1351.

Mugnaini, C., F. Manetti, J. A. Este, I. Clotet-Codina, G. Maga, R. Cancio, M. Botta, and F. Corelli. 2006. Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors. Bioorg Med Chem Lett. 16 (2006) 3541-3544

Cancio, R., A. Mai, M. Artico, G. Sbardella, I. Clotet-Codina, J. A. Este, E. Crespan, S. Zanoli, U. Hubscher, S. Spadari, and G. Maga. 2006. N-N-DABOs are slow binding, tight binding HIV-1 reverse transcriptase NNRTI with broad spectrum activity towards drug resistant mutants.CemMedChem In press.

Pauls, E., J. Senserrich, B. Clotet, and J. A. Este. 2006. Dual role of p53 in HIV-1 infection. Journal of Leukocyte Bioilogy.  Sep;80(3):659-67,  2006

Pettersson, S., I. Clotet-Codina, J. A. Este, J. I. Borrell, and J. Teixido. 2006. Recent advances in combinatorial chemistry applied to development of anti-HIV drugs. Mini Rev Med Chem 6:91-108.

G Coma, R Pena, J Blanco, A Rosell, F E. Borras, JA Esté, B Clotet, L Ruiz, R Parkhouse and M Bofill. Direct activation of monocytes with IL-12 plus IL-18 leads to monocyte survival and the production of inflammatory angiogenic and angiostatic chemokines.Clinical & Experimental Immunology, 2006 Sep;145(3):535-44

R Lysek, C Schütz, S Favre, A C. O'Sullivan, C Pillonel, T Krülle, P M. J. Jung, I Clotet-Codina,  J A. Esté and P Vogel. Search for α-glucosidase inhibitors: new N-substituted valienamines and conduramine F-1 derivatives- Bioorgan Med Chem, 2006 Sep 15;14(18):6255-82. 2006

Colobran, R., Adreani, P., Ashhab, Y., Llano, A., Este, J. A., Dominguez, O., Pujol-Borrell, R. and Juan, M., Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV+ patients. J Immunol 2005. 174: 5655-5664.

Llano, A. and Este, J. A., Chemokines and other cytokines in HIV-1 infection. Inmunología 2005. 24: 246-260.

Lopez-Aldeguer, J., Aguirrebengoa, K., Arribas, J. R., Este, J. A. and Kindelan, J. M., New targets and new drugs in the treatment of HIV. Enferm Infecc Microbiol Clin 2005. 23: 33-40.

Lopez-Aldeguer, J., Aguirrebengoa, K., Arribas, J. R., Este, J. A. and Kindelan, J. M., New targets and new drugs in the treatment of HIV. Enferm Infecc Microbiol Clin 2005. 23 Suppl 2: 25-32.

Manetti, F., Este, J. A., Clotet-Codina, I., Armand-Ugon, M., Maga, G., Crespan, E., Cancio, R., Mugnaini, C., Bernardini, C., Togninelli, A., Carmi, C., Alongi, M., Petricci, E., Massa, S., Corelli, F. and Botta, M., Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity. J Med Chem 2005. 48: 8000-8008.

Moncunill, G., Negredo, E., Bosch, L., Vilarrasa, J., Witvrouw, M., Llano, A., Clotet, B. and Este, J. A., Evaluation of the anti-HIV activity of statins. AIDS 2005. 19: 1697-1700.

Pauls, E. and Este, J. A., Interferent RNA as a tool in target validation. Drug Discovery Today, Technologies 2004. 1: 135-140.

Bobardt, M. D., Armand-Ugon, M., Clotet, I., Zhang, Z., David, G., Este, J. A. and Gallay, P. A., Effect of polyanion-resistance on HIV-1 infection. Virology 2004. 325: 389-398.

Rangel, H. R., Weber, J., Chakraborty, B., Gutierrez, A., Marotta, M. L., Mirza, M., Kiser, P., Martinez, M. A., Este, J. A. and Quinones-Mateu, M. E., Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness. J Virol 2003. 77: 9069-9073.

Lopez, S., Armand-Ugon, M., Bastida, J., Viladomat, F., Este, J. A., Stewart, D. and Codina, C., Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Activity of Lectins from Narcissus Species. Planta Med 2003. 69: 109-112.

Llano, A., Barretina, J., Gutierrez, A., Clotet, B. and Este, J. A., Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. J Virol 2003. 77: 4389-4395.

Este, J. A., Virus Entry as a Target for Anti-HIV Intervention. Curr Med Chem 2003. 10: 1617-1632.

Este, J. A., Retroviruses and Opportunistic Infections--Tenth Conference. 10-14 February 2003, Boston, MA, USA. IDrugs 2003. 6: 279-281.

Blanco, J., Barretina, J., Ferri, K. F., Jacotot, E., Gutierrez, A., Armand-Ugon, M., Cabrera, C., Kroemer, G., Clotet, B. and Este, J. A., Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events. Virology 2003. 305: 318-329.

Barretina, J., Blanco, J., Armand-Ugon, M., Gutierrez, A., Clotet, B. and Este, J. A., Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther 2003. 8: 155-161.

Barretina, J., Junca, J., Llano, A., Gutierrez, A., Flores, A., Blanco, J., Clotet, B. and Este, J. A., CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 2003. 82: 500-505.

Armand-Ugon, M., Gutierrez, A., Clotet, B. and Este, J. A., HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003. 59: 137-142.

Armand-Ugon, M., Quinones-Mateu, M. E., Gutierez, A., Barretina, J., Blanco, J., Schols, D., De Clercq, E., Clotet, B. and Este, J. A., Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir Ther 2003. 8: 1-8.

R. Pascual, M. Mateu, J. Gasteiger, J. I. Borrell, J. Teixidó.  Design and Analysis of a Combinatorial Library of HEPT analogues: Comparison of Selection Methodologies and Inspections of the Actually Covered Chemical Space. Journal of Chemical Information and Computer Sciences 2003. 43:199.

Pacheco R., Martinez-Navio J. M.,  Lejeune M., Climent N. , Oliva H.,  Gatell J. M., Gallart T.,  Mallo J.,  Lluis C.,  Franco R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse R PNAS July 5, 2005 vol. 102 no.27 9583-9588 www.pnas.org cgi doi 10.1073 pnas.0501050102

Dr Joan Fibla Palazón

Dr Montserrat  Plana Prades

Dr Antonio José Caruz Arcos

Dr Benito Regueiro Garcia

Nieto G, Barber Y, Rubio M, Rubio M and Fibla J. Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients. Journal of Steroid Biochemistry and Molecular Biology 2004;89-90C:199-207

Fibla J. Cofactores genéticos del huésped en la vulnerabilidad a la infección por VIH-1 y progresión del sida. AIDS Cyber Journal 2003; 6:15-24

Libois A, Lopez A, Garcia F, et al. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 2006;22:657-66

Manuel Sánchez de la Torre, Carmen Torres, Gema Nieto, et al. Submitted Association of promoter and 3'UTR polymorphisms of vitamin D receptor gene with human immunodeficiency virus Type 1 infection in intravenous drug users (submitted feb 2007).

Gutiérrez-Sanmartín D, Varela-Ledo E, Aguilera A, et al. Implication of P38 mitogen-activated protein kinase (MAPK) isoforms (α, Β, γ AND δ) in CD4+ T cells infection By Human Immunodeficiency Virus Type-1 (submitted feb 2007).

Dr Rafael Franco Fernández

R Pacheco, FCiruela, V Casadó, J Mallol, T Gallart, C Lluis, R Franco. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. Copyright 2004 by The American Society for Biochemistry and Molecular Biology, Inc. (in press).

Angulo E., Casadó V., Mallol J., Canela EI., Viñals V., Ferrer I., Lluis C., Franco R. A1 Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer's Disease and Mediate 80th Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation (publication pending).

Pacheco,R., Martínez-Navio, J.M., Lejeune, M., Climent, N., Oliva,H., Gatell,J.M., Gallart,T., Mallol,J., Lluis,C., Franco,F. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse PNAS, july 5, 2005, vol.102/n.27/9583-9588

Pacheco,R., Ciruela,F., Casadó,V., Mallol,J., Gallart,T., Lluis,C., Franco,R. Group I Metabotropic Glutamate Receptors Mediate a Dual Role of Glutamate in T Cell Activation The Journal of Biological Chemistry (2004) Vol.279, N.32, issue of august 6, 33352-33358

Pacheco,R., LLuis,C., Franco,R. Role of CD26-ademosine deaminase interaction in T cell-mediated immunity Inmunología, Vol.24, N.2, abril-junio 2005: 235-245

Rodrigo Pacheco, Francisco Ciruela, Vicent Casado´, Josefa Mallol, Teresa Gallart, Carmen Lluis, and Rafael Franco (2004) Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation J. Biol. Chem. 279. 33352-33358

Rodrigo Pacheco, Carmen Lluis and Rafael Franco (2005) Role of CD26-adenosine deaminase interaction in the T cell-mediated immunity Inmunología 24, 235-245

Rodrigo Pacheco, Harold Oliva, Jose M. Martinez-Navío, Nuria Climent, Francisco Ciruela, Jose M. Gatell, Teresa Gallart, Josefa Mallol, Carmen Lluis, and Rafael Franco (2006) Glutamate Released by Dendritic Cells as a Novel Modulatorof T Cell Activation.J. Immunol., 2006, 177: 6695-6704.

Rodrigo Pacheco; Teresa Gallart; Carmen Lluis; Rafael Franco (2007) Role of glutamate on T-cell mediated immunity J. Neuroimmunol. in press

Dr  Josep M .Gatell Artigas

Felipe García, Merylene Lejeune, Nuria Climent, Cristina Gil, José Alcamí, Vanessa Morente, Llucia Alós, Alba Ruiz, Javier Setoain, Emilio Fumero, Pedro Castro, Anna López, Anna Cruceta, Carlos Piera, Eric Florence, Arturo Pereira, Agnes Libois,  Nuria González, Meritxell Guilá, Miguel Caballero, Francisco Lomeña, José M Miró, Tomás Pumarola, Montserrat Plana, José M Gatell, Teresa Gallart. Therapeutic  immunization with  dendritic cells loaded with inactivated autologous hiv-1 in chronic hiv-1 infected  patients: a pilot randomized trial. J Infect Dis 2005;191:1680-1685

García F. Vacunas terapéuticas en la infección por VIH REF. En González J, Moreno S, Rubio. Infección por VIH 2005. Publicaciones Permanyer. Madrid 2005.

Felipe García, Lidia Ruiz1, Juan Carlos López Bernaldo de Quirós 2, Santiago Moreno3, Pere Domingo4. Inmunoterapia y vacunas terapeuticas en la Infección por VIH. Enfermedades Infecciosas y Microbiología Clínica  2005; 23 (Sup 2): 84-94.

Alex Soriano, Francisco Lozano, Harold Oliva, Felipe García, Meritxell Nomdedéu, Elisa De Lazzari, Carmen Rodríguez, Alicia Barrasa, José I. Lorenzo, Jorge del Romero, Montserrat Plana, José M. Miró, José M. Gatell, Jordi Vives, Teresa Gallart. Interleukin 4 receptor (IL-4R) polymorphisms: influence on susceptibility to HIV-1 infection and on progression to AIDS Immunogenetics 2005; 57: 644-54

Alba Ruiz, Meritxell Nomdedeu, Marisa Ortega, Merylene Lejeune, Javier Setoain, Núria Climent, Emilio Fumero, Montserrat Plana, Carlos Piera, Francisco Lomeña, Jose M Gatell, Felipe García, Teresa Gallart. Migration of HIV-1 loaded dendritic cells labelled with 111In-oxine used as a therapeutic vaccine in HIV-1 infected patients (in revision)

Dr   Juan Pablo Horcajada Gallego

Muñoz A., Suárez B., Lozano F., Smithson A., Vives J. , Mensa J., Horcajada J.P.  Polymorphisms of the mannose-binding lectin gene and susceptibility to opportunistic infections in HIV-infected patients. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington Convention Center, Washington, DC. (abstract H-1763/341).

Lozano F.,  Suárez B., Muñoz A., Jens C. Jensenius, Mensa J., Vives J.,  Horcajada J.P. Novel masp2 variants detected among northafrican and sub-saharan individuals. Tissue Antigens 2005;66:131-5.

Smithson A, Muñoz A, Suarez B, Soto SM, Perello R, Soriano A, Martinez JA, Vila J, Horcajada JP, Mensa J, Lozano F. Association between Mannose-Binding Lectin Deficiency and Septic Shock following Acute Pyelonephritis Due to Escherichia coli. Clin Vaccine Immunol 2007;14:256-61.

A Muñoz, F Lozano, B Suárez, C. Fariñas, A Smithson, JM Gatell, J Mensa,  JP Horcajada. Polymorphic receptors of the innate immune system (mbl, tlr) and susceptibility to bacterial infections in hiv-infected patients: a case-control study. Mol Immunol 2007 (under review).

Dr  Miguel Angel Martínez de la Sierra

Parera M., Ibañez A., Clotet B., Martinez MA. Lack of evidence for protease evolution in HIV-1 infected patients after two years on suppressive HMRT. Journal of Infectious Diseases, 18: 1444-51, 2004.

Tapia N., Fernández G., Gómez-Mariano G., Parera M., Clotet B., Quiñones-Mateu M., Domingo E., Martínez MA. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in synergistic inhibition of HIV-1 infection,  Virology, 338:1-8.

Giménez-Barcons M., Ribera M., Llano A., Clotet B., Esté JA. and Martínez MA. (2005). Analysis of chemokine and cytokine expression in HIV-1 and GB virus-C co-infected patients. Clinical Infectious Diseases,.40: 1342-1349.

Tapia N., Fernández G., Gómez-Mariano G., Parera M., Clotet B., Quiñones-Mateu M., Domingo E. and Martínez MA. (2005). Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology, 338:1-8

Sabariegos R., Jiménez-Barcons M., Tapia N., Clotet B., and Martínez MA. (2006). Human immunodeficiency virus type 1 sequence homology requirements to escape from short interfering RNAs. Journal of Virology, 80: 571-577.

Fernández G., Llano A., Esgleas M., Clotet B., Esté JA. and Martínez MA. (2006). Purifying selection of CCR5-tropic HIV-1 variants in AIDS subjects that have developed syncytium-inducing CXCR4-tropic viruses. Journal of General Virology, 87,1285-1294

Parera M., Fernandez G., Clotet B. and Martínez MA. Exploring the catalytic activity robustness of the HIV-1 protease by single random amino acid substitutions. Mol. Biol. Evol. 2007 (in press)

Dr  Xavier Martínez Picado

Draenert, R., T. M. Allen, Y. Liu, T. Wrin, C. Chappey, C. L. Verrill, G. Sirera, R. L. Eldridge, M. P. Lahaie, L. Ruiz, B. Clotet, C. J. Petropoulos, B. D. Walker, and J. Martinez-Picado. 2006. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. Journal Experimental Medicine 203:529-539

Dr  José Luis Mate Sanz

Navarro JT, Ariza A, Ribera JM, Castella E, Junca J, Tural C, Nomdedeu JF, Bellosillo B, Serrano S, Granada I, Milla F, Feliu E, Mate JL, Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. Hum Pathol 2004;35:632-635.

Ribera JM, Navarro JT: Linfomas en pacientes con infección por el VIH. Las cosas han cambiado para bien. Enferm Infecc Microbiol Clin 2004; 22:313-314.

Navarro JT, Lloveras N, Ribera JM, Oriol A, Feliu E., Mate JL. The prognosis of HIV-infected patients with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005; 90:704-705

Navarro J.T., Ribera J.M., Oriol A., Xicoy B.,  Sirera G., Lloveras N., Millá F., Feliu E., Mate J.L.. Advanced stage is the best prognostic factor for survival in patients with systemic AIDS-related non-Hodgkin lymphoma treated with CHOP and HAART. International Journal of Hematology (sent)

Dr Òscar Miró Andreu

Casademont J., Sanjurjo E., Garrabou G., Miró O. Diagnosis of mitochondrial dysfunction in HIV-infected patients under highly active antiretroviral therapy: possibilities beyond the standard procedures. Antiviral Ther 2005; 10(supl. 2):M65-M71.

Casedemont J., Miró O., Cardellach F. Secondary defects of the mitochondrial respiratory chain: The examples of neuroleptic use, CO toxicity and HIV treatment. En: Villarroya F, ed. New frontiers in Mitochondrial Biogenesis and disease 2005, (in press).

Ballesteros AL., Miró O., López S., Fuster O., Videla S., Martínez E. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatrement with didanosine, stavudine or both. Antivir Ther 2004, 9:969-977.

Negredo E., Moltó J., Burger O., Caté H., Miró O., Ribalta J. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). JAIDS 2005, 38:47-52.

Miró O., López S., Rodríguez M., Martínez E., Pedrol E., Garrabou G. Upregulatatory mechanisms compensate for mtONA depletion in asymptomatic individuals receiving stavudine plus didanosine. JAIDS 2004, 37:1550-1555.

Miró O., López S., Martínez E., Pedrol E., Milinkovic A., Oeig E. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004, 39:710-716.

López S., Miró O., Martínez E., Pedrol E., Rodríguez-Santiago B., Milinkovic A. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004, 9:47-55.

Miró O., López S., Pedrol E., Rodríguez-Santiago B., Martínez E., Soler A. Mitochondrial DNA depletion and respiratroy chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected pat.ients with HAART-related lipodystrophy. Antivir Ther 2003, 8:333-338.

Miró O., López S., Martínez E., Rodríguez-Santiago B., Blanco JL. Milinkovic A. Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy. AIDS Res Hum Retrovir 2003, 19:1027-1032.

Garrabou G, López S, Sanjurjo E, Infante AB, Larrousse M, Milinkovic A, et al. Mitochondrial function in HAART-related hyperlactatemia. Antivral Ther 2005; 10:L43 ; abstract 70, 7th International Workshop on Adverse Drug reactions and Lipodystrophy in HIV, Dublin, 13-16  nov. 2005 (in preparation).

Garrabou G, Sanjurjo E, Miró O, Manrtínez E, Infante AB, López S, et al. Non-invasive diagnosis of mitochondrial dysfunction in HAART-related hyperlactatemia. Clin Infect Dis 2006; 42:584-585.

Pedrol E, Ribell M, Deig E, Villà MC, Miró O, Garrabou G, et al. Tratamiento de la hiperlactatemia sintomática y de la acidosis láctica en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa análogos de los nucleósidos. Med Clin (Barc) 2005; 125:201-204.

Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005; 353:2305-2306.

Garrabou G, Soriano A, López S, Guallar J, Giralt M, Villarroya F, et al. Reversible inhibition of mitochondrial protein synthsis during linezolid-related hyperlactatemia. Antimicrob AgentsChemother 2007 (in press)

Dr  Robert Muga Bustamante

Dr  Ildefonso Hernández Aguado

R. Muga. La larga sombra del VIH/sida en los hospitales.Med Clin(Barc)2004;122(l):21-3.

R Muga, J M Egea, A Sanvisens, J Arnal, C Tural, J Tor, C Rey-Joly. Impact of injecting drug use on the interruption of antiretroviral therapies. J Epidemiol Commun;ty Heolth 2004;58:286-287. doi: 1 0.1136/jech.2003.01 0066

Muga R, et al. Evaluación de drogadictos con enfermedades asociadas. Aspectos clínicos y terapéuticos de la atención integral. Med Clin (Barc) 2004; 122(16); 624-635.

Langohr K., Gomez G., Muga R. A parametric survival model with an interval-censored covariate. Statistics in Medicine 2004, 23:3159-3175.

Fuster D., Planas R., Muga R., Ballesteros AL., Santos J., Tor J., Sirera G., Guardiola H., Salas A., Cabré E., Ojanguren I., Barluenga E., Rey-Joly C., Clotet B., Tural C. Advanced liver fibrosis in HIV/ HCV coinfected patients on antiretroviraltherapy. AIDS Res Hum Retroviruses 2004; 20:1293-1297.

Muga R., Sanvisens A., Bolao F., Tor J., Rey-Joly C., Pujo] R., Muñoz A., Fuster D., Santesmases J. Temporal changes of HIV and Hepatitis C virus infections among injecting drug users. (in preparation).

Langhor K., Muga R., Sanvisens A., Serra I., Tor J., Rey-Joly C. Study on hepatic markers among intravenous drug users with and without HIV infection. (in preparation).

Muga R, Egea JM, Sanvisens A,  et al. Impact of Injecting Drug Use on Discontinuation of Antiretroviral Therapy. J Epidemiol Community Health  2004; 58:286-7

Rivas I, Santesmases J,  Tor J, et al. Paciente con infección por VIH en tratamiento con metadona. Tratornos adictivos 2005, 7:226-34

Muga R, Sanvisens A, Bolao F, et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injecting drug users from metropolitan Barcelona: 1987-2001 Drug Alcohol Depend 2006;82 Suppl. 1: S29-S33

Lumbreras B, Jarrín I, del Amo J, et al. Impact of Hepatitis C infection on long-term mortality of injecting drug users with and without HIV infection from 1990 to 2002: defferences before and after HAART. AIDS 2006, 20:111-116

Tural C, Solà R, Rubio R, et al. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. J Viral Hepat 2006 (in press)

Jarrin I, Lumbreras B, Ferreros I, et al. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART. Int J Epidemiol 2006 (in press)

Muga R, Langohr K, Sanvisens A, et al. HIV Infection Modifies the Effect of Hepatitis C on Liver Enzyme Alterations. J Viral Hepat 2006 (sent).

Muga R, Langohr K, Tor J, et al. Survival of HIV-positive injection drug users in the era of HAART relative to gender-and-age specific survival of HIV-negative users. Clin Infect Dis 2007 (in press)

Romero-Gómez M, Tural C, Solà R, et al. Insulin resistance in co-infected HCV/HIV patients: a negative factor influencing sustained response to peginterferon plus ribavirin. AIDS 2006, enviat.

González V, Martró E, Folch C, et al. Detection of hepatitis C virus-antibodies in Gingival Crevicular Fluid (GCF) for prevalence studies. J Clin Microbiol 2006, enviat

Ferreros I, Lumbreras B, Hurtado I, et al. The shifting pattern of cause-specific mortality in cohorts of HIV infected and non-infected people. AIDS 2007, enviat.

Hepatoproteomics of chronic hepatitis C in patients with HIV infection. (in preparation)

Prevalence of liver fibrosis in HCV monoinfected and HCV/HIV coinfected patients according to clinical indexes. (in preparation)

Hepatitis C virus infection among injection drug users. Natural history and survival of HCV monoinfected and HCV/HIV coinfected patients. (in preparation)

and Correlation of TGF Hialuronic acid with liver fibrosis in HCV/HIV coinfected patients. (in preparation)

Impact of HIV and Hepatitis C virus infectious on specific-cause mortality in a community-based cohort of injecting drug users from 1990 to 2006. (in preparation)

Dr  Pura Muñoz Cánoves

Dr Guido Poli

Dr Francesco Blasi

Alfano M., Sidenius N., Blasi F., Poli G. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. J Leukoc Biol 74:750-756, 2003.

Alfano M., Poli G. The HIV life cycle: multiple targets for antiretroviral agents. Drug Design Reviews - Online, 1:83-92, 2004.

Resnati M., Pallavicini I., Daverio R., Sidenius N., Bonini P., Blasi, F. Production of monoclonal antibodies and development of and immunofluorimetric assay specific for the chemotactic epitope of the urokinase receptor (uPAR), (submitted). 

Selleri C., Montuori N., Ricci P., Visconte V., Carriero, MV, Sidenius N., Serio B., Blasi F., Rotoli B., Rossi G., Ragno P. Involvement ofthe urokinase-type plasminogen activator receptor in hematopoietic stem cell. Blood 105:2198-2205 (2005)

Mondino A., Blasi F. UPA and uPAR in fibrinolysis, irnmunity and pathology. Trends in Immunology 25, 450-455, 2004.

Furlan F., Orlando S., Laudanna C., Resnati M., Basso V., Blasi F., Mondino, A. A soluble form of the urokinase receptor inhibits monocyte migration by preventing integrin-dependent cell adhesion. J. Cell Sci., 117, 2909-2916, 2004.

Cinque P., Nebuloni M., Santovito M., Price RW., Gisslen M., Hagberg L., Bestetti A., Vago G., Lazzarin A., Blasi F., Sidenius N. The urokinase plasminogen activator receptor is highly expressed in brain tissue and cerebrospinal fluid of patient with AIDS dementia complex and other HIV-related neurological manifestations. Ann. of Neurol., 55, 687-694, 2004.

Sidenius N., Nebuloni M., Sala S., Zerbi P., Price RW., Gisslen M., Hagberg L., Vago L., Lazzarin A., Blasi F., Cinque P. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J. Neuroimmunol. 157:133-139, 2004.

M. Alfano, L. Cassetta, & G. Poli. Glycosyl phosphatidyl-inositol-anchored proteins and HIV infection. Letters in Drug Design & Discovery, 3:598-604, 2006.

C. Elia, E. Cassol, N. Sidenius, F. Blasi, A. Castagna, G. Poli, & M. Alfano. Urokinase-Type Plasminogen Activator Inhibits HIV-1 Replication in Human Macrophages and U1 Promonocytic Cells. Role of Vitronectin. (Submitted)

M. Alfano, C. Elia, N. Sidenius, R. Pardi, F. Blasi, C. Laudanna, & G. Poli. uPA/uPAR interaction inhibits HIV expression via activation of small GTPase RhoA, PKCe and b integrin clusterization. (In preparation)

Lopez-Alemany R, Suelves M,  Muñoz-Canoves P. Plasmin generation dependent on a-enolase-type plasminogen receptor is required for myogenesis. Thromb Haemost. 90: 724-733, 2004.

Lopez-Alemay R, Suelves M, Diaz-Ramos A, Vidal B, Muñoz-Canoves P. Alpha-enolase plasminogen receptor in myogenesis. Front. Biosci. 10: 30-36, 2005

Lluís F, Ballestar E, Suelves M, Esteller M, Sartorelli V, Muñoz-Cánoves P. E47 phosphorylation by p38 MAP kinase promotes MyoD/E47 association and muscle-specific gene transcription. EMBO J. 24: 974-984, 2005

Vidal B, Parra M, Jardi M, Saito S, Appella E, Muñoz-Cánoves P. The alkylating carcinogen N-methyl-N'-nitro-N-nitrosoguanidine activates the plasminogen activator inhibitor-1 gene through sequential phosphorylation of p53 by ATM and ATR kinases. Thromb Haemost. 93: 584-91, 2005

Nagamine Y, Medcalf RL, Muñoz-Cánoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost. 93:661-675, 2005

Suelves M, Vida1 B, Ruíz V, Baeza-Raja B, Díaz-Ramos MA, Cuartas I, Lluís F, Parra M, Jardí M, López-Alemany R, Serrano A, Muñoz-Cánoves P. The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). Front. Biosci. 10:2978-2985, 2005

Lluis F, Perdiguero E, Nebreda AR, Muñoz-Cánoves P. Regulation of  skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 16:36-44, 2006.

Suelves M, Serrano AL, Muñoz-Canoves P. Impaired regeneration and fiber type-specific atrophy in muscles of Tg26 transgenic mice. (in preparation)

Vidal B, Suelves M, Serrano AL, Muñoz-Cánoves P. uPA receptor (uPAR) is dispensable for skeletal muscle regeneration. (in preparation)

Mondino, A. and Blasi. F..  UPA and uPAR in fibrinolysis, immunity and pathology. Trends in Immunology. 25, 450-455 (2004). 

Furlan, F., Orlando, S.,, Laudanna, C., Resnati, M., Basso, V.,  Blasi, F.  and Mondino, A. A soluble form of the urokinase receptor inhibits monocyte migration by preventing integrin-dependent cell adhesion. J. Cell Sci., 117, 2909-2916, (2004).

Cinque, P., Nebuloni, M., Santovito, M., Price, R.W., Gisslen, M., Hagberg,, L., Bestetti, A., Vago, G., Lazzarin, A., Blasi, F. and Sidenius, N. The urokinase plasminogen activator receptor is highly expressed in brain tissue and cerebrospinal fluid of patient with AIDS dementia complex and other HIV-related neurological manifestations. Ann. of Neurol., 55, 687-694 (2004).

Sidenius, N, M.Nebuloni, S.Sala, P. Zerbi, R.W. Price, M. Gisslen, L. Hagberg, L. Vago, A. Lazzarin, F. Blasi  and P. Cinque. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J. Neuroimmunol. 157:133-139. 2004.

Bernard Degryse, Massimo Resnati, Ralf-Peter Czekay, David J. Loskutoff, and Francesco Blasi. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem., 280, 24792-24803 (2005).

Resnati, M., Pallavicini, ,I,, Daverio, R., Sidenius, N., Bonini, P. and Blasi, F. Production of monoclonal antibodies and development of an immunofluorimetric assay specific for the chemotactic epitope of the urokinase receptor (uPAR). J. Immunol. Methods  308, 192-202 (2006).

Rizzi, C,  Massimo P. Crippa, Rienk Jeeninga, Ben Berkhout, Francesco Blasi, Guido Poli, & Massimo Alfano. Pertussis Toxin B-oligomer Suppresses IL-6 Induced HIV-1 and Chemokine Expression  in Chronically Infected U1 Cells Via Inhibition of AP-1. (2005) J. Immunol., 176,  999-1006 (2006).

Mazzieri, R., D'Alessio, S., Kamgang-Kemhoe, R., Ossowski, L. and Blasi, F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.  Mol Biol Cell. 17, 367-78, (2006).

Dr  Román Pallarés Giner

Fenoll A, Liñares J, Pallares R. The Spanish Pneumococcal Infection Study Network (G03/103). The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003; 22:S15-S24.

Grau I, Tubau F, Schulze M H, Llopis F, Podzamczer D, Liñares J, Gudiol F. Pallares R. Epidemiologic changes in bacteremic pneumococcal disease in patients with Human Immunodeficiency Virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-1540.

Ardanuy C, Tubau F, Liñares J, Dominguez MA, Martin R., Pallares R. Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes. Antimicrob Agents Chemother 2005, 49(2):827-9.

Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E,  Martin R, Liñares J., Pallarés R. Erythromycin-resistant Streptococcus pneumoniae isolated in Spain: Serotypes, clones and mechanisms of resistance. Antimicrob Agents Chemother 2007 (manuscrit en fase de revisió).

Liñares J, Ardanuy C, Fenol A, Tubau F, Pallares R. Martín R. Activity of telithromycin agains Streptococcus pneumoniae-erythromycin resistant and susceptible. (in preparation).

Grau I, Podzamczer D, Liñares J. Pallares R. Impact of 23-valent pneumocococal vaccine on the distribution of serotypes and clones of Streptococccus pneumonaie in HIV-infected patients.(in preparation).

Dr  Cristòbal Richart Jurado

Domingo P., Vidal F., Domingo J.C., Veloso S., Sambeat M.A.,Torres F., Sirvent J.J., Vendrell J.,  Matias-Guiu X., Richart C. on behalf of the HIV-FRS Study Group. Tumor necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-I-infected patiens: potential role in subcutaneous adipocyte apoptosis European Journal of Clinical Investigation (2005) 35.771-780

Dr  Francesc Vidal Marsal

Dr Hernando Knobel Freud

Dr Juan Antonio Arroyo Diaz

Dr Santiago Montull Morer

Dr David Dalmau Juanola

Peraire J., Miró O., Saumoy M., Domingo P., Pedrol E., Villarroya F., Martínez E., López-Dupla M., Garrabou G., Antònia Sambeat Ma., Deig E.,  Villarroya J., Chacón M. R., López S., Fontanet A., Holmstrom M., Giralt M., Gatell J.M., Vidal F. HIV-1-Infected Long-Term Non-Progressors have Milder Mitochondrial Impairment and Lower Mitochondrially-Driven Apoptosis in Peripheral Blood Mononuclear Cells than Typical Progressors Current HIV Research, 2007;5:467-473

Peraire J., Vidal F., Plana M., Domingo P., Coll B., Vilade C., Garcia F., Veloso S., Gatell J.M., Broch M. Polymorphisms in the 30 untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression AIDS 2007, 21:891-893

Peraire J., Domingo P., Broch M., Knobel H., Pedrol E., Vidal F. et al. Lack of association of SDF-1 3'A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years. J Acquir Immune Defic Syndr 2005;40:276-279.

Viladés C., Domingo P., Broch M., Pedrol E., Knobel H., Dalmau D., Vidal F., et al. Spanish HIV-1-infected long-term nonprogressors of more than 15 years have na increased frequency of the CX3CR1 249I variant allele. J Acquir Immune Defic Syndr 2005;40:527-531.

Peraire J., Domingo P., Broch M., Cairo M., Pedrol E., Vidal F., et al. Polymorphism of RANTES chemokine gene promoter is not associated with long term non-progressive HIV-1 infection of more than 16 years. J Acquir Immune Defic Syndr 2006;41:17-22.

Peraire J., Broch M., Domingo P., Pedrol E., Dalmau D., Knobel H., et al. Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards. J Acquir Immune Defic Syndr 2006;42:383-383.

Viladés C., Broch M., Plana M., Domingo P., Alonso-Villaverde C., Pedrol E., Knobel H., Dalmau D., Peraire J., Gutiérrez C., López A., Sambeat M.A., Olona M., Garcia F., Richart C., Gatell J.M., Vidal F. Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection : CCL2 -2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr 2007;44 (in press).

Peraire J., Plana M., Domingo P., Coll B., Garcia F., Veloso S., Gatell J.M., Broch M., Vidal F., CX3CL1. AIDS 2007 (ref A-1640R1) (in press).

Saumoy M., Peraire J., Sauleda S., Martinez-Vea A., Viladés C., Vidal F., et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004;18:1741-1742.

Domingo P., Domingo J.C., Vidal F. Molecular basis of antiretroviral drugs-associated long-term toxicity: how bad can good drugs be?. Antiinfect Agents in Med Chem 2004;3:109-131.

Domingo P., Domingo J.C., Veloso S., Sambeat M.A., Torres F., Vidal F., et al. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potental role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005;35:771-780.

Domingo P., Vidal F. Toxicidad a largo plazo de los análogos de nucleósidos/nucleótidos. Enferm Infecc Microb Clin 2006;Monog 5(1):22-29.

Domingo P., Vidal F. Manejo de la toxicidad asociada a análogos de los nucleósidos o cómo sustituir fármacos sin incrementar la complejidad del régimen. Enf Infecc Microb Clin 2006;5:45-53.

Domingo J.C., Guallar J., Saumoy M., Cordobilla B., Sanchez de la Rosa R., Giralt M., Alvarez M.L., López-Dupla M., Torres F., Villarroya F., Cihlar T., Domingo P.,  Vidal F. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with various antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006;50:3824-3832.